Recently, Dapu Biotech Co., Ltd. made an exciting announcement regarding the successful conclusion of its Series B2 funding round. This round was spearheaded by the Intellectual Property Fund, a key entity under the Shanghai Science and Technology Innovation Group.

The freshly acquired funds are earmarked for several crucial initiatives. Firstly, they will fuel the acceleration of the global commercialization of Dapu Biotech's diverse range of self-developed, high-end life science instrument products. Secondly, the investment will enhance the application efficiency throughout the entire drug discovery and synthetic biology process, spanning from research and development to production. Additionally, it will drive the integrated innovation of artificial intelligence (AI) and biotechnology.

Dapu Biotech, which was incubated at the Hong Kong University of Science and Technology and officially established in 2018, has emerged as a frontrunner in China's droplet microfluidics sector. The company is steadfastly committed to delivering world-class life science tools.